Despite scientific research, brain cancer remains the most malignant form of cancer known to humankind, rapidly progressive and uniformly fatal, despite treatments ranging from surgery to radiation to chemotherapy. In the past 25 years, only two new treatments for brain cancer have been FDA approved and while some scientists and doctors are working hard toward a cure, the lack of funding and awareness for the disease -- coupled with the survival rate of patients -- leaves brain cancer to be classified as an 'orphaned' disease. With the unveiling of CABTT, Seattle-based doctors and researchers are working in collaboration to establish community-based clinical trials to further execute their research and increase the survivability and quality of life for patients diagnosed with brain cancer.
"Until recently, patients who received a brain-cancer diagnosis in the Pacific Northwest had few options for access to truly state-of-the-art facilities," said CABTT Director and SNI Neurosurgeon Gregory Foltz, M.D. "Brain cancer is a very aggressive, terminal disease, and most patients were previously faced with traveling to receive the best possible care and access to clinical trials, taking away precious time with their loved ones and leaving them with a sense of hopelessness. Our vision for CABTT is to create a facility that enables patients to actively participate in clinical trials expediting the approval process for new treatments and rivaling the top treatment centers in the country."
Advanced Technology Fuels Patient Care
Incorporated into the coordinated patient-care clinic, CABTT is home to
a comprehensive brain-tumor research laboratory that provides rapid genetic
analysis of all patient tumors.
|SOURCE Swedish Neuroscience Institute|
Copyright©2008 PR Newswire.
All rights reserved